Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of CNS-242 to lower serum uric acid and prevent gout attacks
2005-001143-31Phase 2Completed
- Sponsor
- Nissui
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CNS-242 in gout and hyperuricemia (2 arms), sponsored by Nissui. Started May 2005; status: completed.
02
Drugs
CNS-242
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on 2005-001143-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001143-31.